NEW FORMS AND TECHNOLOGIES OF INSULIN THERAPY IN TYPE 1 DIABETES - A SYSTEMATIC LITERATURE REVIEW

Introduction: Type 1 diabetes is a chronic autoimmune disease that leads to permanent lack of insulin. In recent years, advances in insulin formulations and delivery methods have improved the ability to mimic natural insulin secretion and support better diabetes management. Aim: The aim of this article is to review the most commonly used forms of insulin therapy and modern technologies supporting the treatment of type 1 diabetes, with attention to their effectiveness, safety, and impact on patients’ quality of life. Methods: A search of PubMed and ScienceDirect was performed for publications from January 2008 to June 2025. The review included clinical trials and review articles about insulin therapy in type 1 diabetes. Titles and abstracts were screened, full texts were analysed, and reference lists of key papers were checked. Results: Modern insulin therapy is based on insulin analogues with different action profiles and on delivery systems such as insulin pens, pumps, and hybrid closed-loop devices. New basal and prandial analogues help improve glycaemic control and reduce complications. Automated Insulin Delivery systems increase time in range and improve daily functioning. However, problems such as variability of insulin absorption, lipodystrophy, and high costs still remain. Conclusions: Although progress in insulin therapy has improved diabetes care, further research, better access to modern technologies, and further patient education is essential.

• Publication year

  2025

• Venue

  International Journal of Innovative Technologies in Social Science

• Publication date

  2025-12-30

• Fields of study

  Not labeled

• Identifiers
  DOI 10.31435/ijitss.4(48).2025.4479
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Diabetes Technology Trends: A Review of the Latest Innovations.

  2025cited by this paper
• The Effect of Transition From Multiple Daily Injection Therapy to Automated Insulin Delivery in People With Type 1 Diabetes and Limited Diabetes Self-Management

  2025cited by this paper
• Insulin icodec: A novel once-weekly formulation for the treatment of type 1 and type 2 diabetes mellitus

  2025cited by this paper
• Relationship Between Lipohypertrophy, Glycemic Control, and Insulin Dosing: A Systematic Meta-Analysis

  2024cited by this paper
• Interventions Targeting Insulin Resistance in Patients with Type 1 Diabetes: A Narrative Review

  2024cited by this paper
• Glucose-sensitive insulin with attenuation of hypoglycaemia

  2024cited by this paper
• Once‐weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme

  2024cited by this paper
• Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes

  2024cited by this paper
• What Is the Role of Basal Weekly Insulin in Clinical Practice? The State of the Art

  2024cited by this paper
• Comparative clinical efficacy and safety of insulin glargine 300 U/ml (Toujeo) versus insulin glargine 100 U/ml in type 2 diabetes and type 1 diabetes: A systematic literature review and meta‐analysis

  2023cited by this paper
• Changes in the Global Epidemiology of Type 1 Diabetes in an Evolving Landscape of Environmental Factors: Causes, Challenges, and Opportunities

  2023cited by this paper
• Comparing the effectiveness of continuous subcutaneous insulin infusion with multiple daily insulin injection for patients with type 1 diabetes mellitus evaluated by retrospective continuous glucose monitoring: A real-world data analysis

  2022cited by this paper
• Fully Closed Loop Glucose Control With a Bihormonal Artificial Pancreas in Adults With Type 1 Diabetes: An Outpatient, Randomized, Crossover Trial

  2021cited by this paper
• Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double‐blind meal test early‐phase study

  2021cited by this paper
• The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2021cited by this paper
• 100 years of insulin: celebrating the past, present and future of diabetes therapy

  2021cited by this paper
• Ultra-Rapid-Acting Insulins: How Fast Is Really Needed?

  2021cited by this paper
• Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes

  2020cited by this paper
• Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review

  2020cited by this paper
• The Evolution of Insulin and How it Informs Therapy and Treatment Choices

  2020cited by this paper
• Glycemic Outcomes in Adults With T1D Are Impacted More by Continuous Glucose Monitoring Than by Insulin Delivery Method: 3 Years of Follow-Up From the COMISAIR Study

  2019cited by this paper
• Insulin Detemir Use Is Associated With Higher Occurrence of Hypoglycemia in Hospitalized Patients With Hypoalbuminemia

  2018cited by this paper
• Rethinking the Viability and Utility of Inhaled Insulin in Clinical Practice

  2018cited by this paper
• Factors Affecting the Absorption of Subcutaneously Administered Insulin: Effect on Variability

  2018cited by this paper
• Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial

  2017cited by this paper
• Dose Accuracy, Injection Force, and Usability Assessment of a New Half-Unit, Prefilled Insulin Pen

  2017cited by this paper
• Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus

  2016cited by this paper
• Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.

  2016cited by this paper
• New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)

  2015cited by this paper
• New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)

  2015cited by this paper
• Insulin sensitivity and complications in type 1 diabetes: New insights.

  2015cited by this paper
• Intraperitoneal insulin infusion: treatment option for type 1 diabetes resulting in beneficial endocrine effects beyond glycaemia

  2014cited by this paper
• Systematic review: continuous intraperitoneal insulin infusion with implantable insulin pumps for diabetes mellitus

  2014cited by this paper
• Short Report: Treatment Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal–Bolus Type 1): 2-year results of a randomized clinical trial

  2013cited by this paper
• Glucose-Lowering Effect of Insulin Degludec is Independent of Subcutaneous Injection Region

  2012cited by this paper
• Continuous Intravenous Insulin: Ready for Prime Time

  2008cited by this paper

• No citing papers are available for this paper.